Insmed stock falls 6.56 percent after CFO transition

Published on 10/06/2026 at 14:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Insmed stock heads into October 29 results with 2026 BRINSUPRI guidance of USD 1.25 billion to USD 1.40 billion. ARIKAYCE guidance remains USD 450 million to USD 470 million.

INSM, US4576693075, Illustration mit AI erstellt.

Insmed (ISIN US4576693075) stock was last at USD 103.83 on Nasdaq on October 5, 2026, down 6.56 percent from the prior session. The company announced a CFO transition that keeps the finance chief in place through the third-quarter reporting date, while full-year product guidance stayed unchanged, according to Insmed on October 5, 2026.

CFO transition lands before earnings

Sara Bonstein will step down as Insmed CFO on October 30, 2026, and the company has started a search for her successor. The transition is scheduled immediately after the release of third-quarter results, giving the October earnings update added importance for the leadership handover.

Insmed said management will discuss the third-quarter results during a conference call on October 29, 2026, at 8:00 a.m. ET. The release also stated that the CFO change is unrelated to disagreements over accounting practices, financial statements, internal controls or operations.

Guidance stays in place

Insmed reaffirmed full-year 2026 BRINSUPRI revenue guidance of USD 1.25 billion to USD 1.40 billion and ARIKAYCE revenue guidance of USD 450 million to USD 470 million, according to Insmed. The two ranges show how heavily the near-term investment case depends on commercial execution by the respiratory portfolio.

The company also said it had raised more than USD 4.2 billion in capital during Bonstein's tenure. That financing history gives the transition a balance-sheet dimension, even as management points to cash flow positivity in 2027.

Second-quarter scale is visible

Insmed generated USD 425.5 million of revenue in the second quarter of 2026, up 296 percent from the second quarter of 2025, while net loss narrowed 96 percent to USD 13.2 million, according to Simply Wall St. The quarter provides a measurable backdrop for the guidance ranges now being carried into the third-quarter report.

Analyst sentiment remains positive but the published targets vary. MarketBeat reported a Buy consensus from 25 covering brokerages, including 22 Buy ratings, 2 Strong Buy ratings and 1 Sell rating, with an average 12-month price target of USD 200.57.

Stock remains below yearly high

Insmed's USD 22.5 billion market capitalization and USD 90.39 to USD 212.75 52-week range frame the October 5 move. The last price was 51.2 percent below the 52-week high, while volume reached 5,394,454 shares, making the distance to the yearly peak a central valuation reference.

INSM stock was last at USD 103.83 on Nasdaq on October 5, 2026, at 4:00 p.m. ET. The dated price and the October 29 reporting appointment put execution against the reaffirmed guidance at the center of the next company-specific checkpoint.